Recombinant Rhesus Macaque TFPI Protein (Rhesus Macaque TFPI) Asp 29 - Lys 282 (Accession # Q28864) was produced in human 293 cells (HEK293) at ACROBiosystems.
Rhesus Macaque TFPI is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 31.1 kDa. The predicted N-terminus is Asp 29. DTT-reduced Protein migrates as 41-45 kDa in SDS-PAGE due to glycosylation.
Less than 1.0 EU per μg of the Rhesus Macaque TFPI by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product form or formulation.
See Certificate of Analysis for reconstitution instructions and specific concentrations.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a Nterminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a Cterminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The Cterminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.